Key Highlights

  • QuidelOrtho shares fell approximately 20.34 percent in pre-market trading to $13.00 from Wednesday's close of $16.32.
  • Second quarter revenue rose 2 percent to $630.9 million and adjusted EPS beat estimates at $0.13 versus a $0.04 expected loss.
  • Management cut full-year 2026 guidance, citing weakness tied to China and proposed respiratory testing pricing changes.
  • China revenue declined 23 percent year over year amid uncertainty around proposed diagnostic pricing guidelines.

EPS Beat Overshadowed by Guidance Cut

QuidelOrtho Corporation (NASDAQ:QDEL) traded down approximately 20.34 percent in pre-market activity, near $13.00 versus Wednesday's close of $16.32. Second quarter revenue grew 2 percent to $630.9 million, or nearly 6 percent excluding China, and adjusted EPS of $0.13 beat the $0.04 loss estimate, but the beat was overwhelmed by a cut to full-year guidance.

China and Respiratory Testing Weigh on Outlook

China revenue declined 23 percent year over year due to uncertainty around proposed diagnostic pricing guidelines, with the scope of affected provinces broadening to six from three, and management does not expect near-term improvement. Respiratory testing revenue also came in softer, with positivity rates down markedly versus 2025.

Revised Guidance Points to a Weaker Second Half

Full-year 2026 revenue guidance was revised to $2.52 billion to $2.60 billion, adjusted EBITDA to $540 million to $560 million, and adjusted EPS to $0.65 to $0.90. The company withdrew free cash flow guidance entirely, citing uncertainty around China dynamics and respiratory season timing.

Leadership Emphasizes Capital Discipline

New CFO Michael Young emphasized reducing net debt to 4.3 times adjusted EBITDA by year end and disciplined capital allocation. The company continues expanding its Lyra point-of-care platform, rebranded Alexa, targeting a growing installed base ahead of the 2027 to 2028 respiratory season.

Conclusion

QuidelOrtho's sharp decline despite an earnings beat shows how a full-year guidance cut tied to structural China uncertainty can overwhelm a strong quarterly print. With free cash flow guidance withdrawn, the reaction suggests investors are recalibrating expectations for both 2026 and China's durability.